Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- John P. Fruehauf
- Target Recruit Count
- 52
- Registration Number
- NCT00256282
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 80
- Registration Number
- NCT00235235
- Locations
- 🇺🇸
Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States
🇺🇸Baylor College of Medicine - Methodist Breast Center, Houston, Texas, United States
🇺🇸Arnett Cancer Care, Lafayette, Indiana, United States
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 45
- Registration Number
- NCT00225173
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2009-04-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT00215462
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-03-23
- Target Recruit Count
- 53
- Registration Number
- NCT00215930
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00193089
Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 40
- Registration Number
- NCT00194727
- Locations
- 🇺🇸
University of Washington; Seattle Cancer Care Alliance, Seattle, Washington, United States
Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-07-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT00193362
Chemoradiotherapy in Patients With Localised Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-08-04
- Lead Sponsor
- Trans Tasman Radiation Oncology Group
- Target Recruit Count
- 82
- Registration Number
- NCT00193921
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺Mater Misericordiae Hospital, Brisbane, Queensland, Australia
🇦🇺Calvary Mater Newcastle, Newcastle, New South Wales, Australia
Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-12-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 48
- Registration Number
- NCT00194740
- Locations
- 🇺🇸
University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.